Christine Kim1, Joseph Han2, Tara Wu1, Claus Bachert3, Wytske Fokkens4, Peter Hellings3,5, Claire Hopkins6, Stella Lee7, Joaquim Mullol8, Jivianne T Lee1. 1. Department of Head & Neck Surgery, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA. 2. Department of Otolaryngology, Head & Neck Surgery, Eastern Virginia Medical School, Norfolk, Virginia, USA. 3. Upper Airways Research Laboratory, Department of Otorhinolaryngology-Head and Neck Surgery, University of Ghent, Ghent, Belgium. 4. Department of Otorhinolaryngology, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands. 5. Department of Otorhinolaryngology-Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium. 6. Guy's and St. Thomas' NHS Foundation Trust, London, UK. 7. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. 8. Department of Otorhinolaryngology, Hospital Clínic Universitari, Barcelona, Spain.
Abstract
OBJECTIVE: To review the current literature regarding the role of biologics in the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP). DATA SOURCES: PubMed/MEDLINE, EMBASE, Cochrane Review, ClinicalTrials.gov. REVIEW METHODS: We conducted a comprehensive review of the literature on clinical studies investigating the efficacy of emerging biologics in CRSwNP, with a focus on randomized controlled trials. CONCLUSIONS: There appears to be promising evidence to support the safety and efficacy of biologics in CRSwNP with and without asthma for select patients. However, additional large-scale randomized studies with longer follow-up are necessary to determine which patients would benefit the most from these novel systemic treatments. IMPLICATIONS FOR PRACTICE: Chronic rhinosinusitis with nasal polyposis refractory to medical and surgical therapy remains a challenging clinical problem for otolaryngologists. However, emerging biologic therapies may offer a new therapeutic option for such patients with recalcitrant disease.
OBJECTIVE: To review the current literature regarding the role of biologics in the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP). DATA SOURCES: PubMed/MEDLINE, EMBASE, Cochrane Review, ClinicalTrials.gov. REVIEW METHODS: We conducted a comprehensive review of the literature on clinical studies investigating the efficacy of emerging biologics in CRSwNP, with a focus on randomized controlled trials. CONCLUSIONS: There appears to be promising evidence to support the safety and efficacy of biologics in CRSwNP with and without asthma for select patients. However, additional large-scale randomized studies with longer follow-up are necessary to determine which patients would benefit the most from these novel systemic treatments. IMPLICATIONS FOR PRACTICE: Chronic rhinosinusitis with nasal polyposis refractory to medical and surgical therapy remains a challenging clinical problem for otolaryngologists. However, emerging biologic therapies may offer a new therapeutic option for such patients with recalcitrant disease.
Authors: Wilma T Anselmo-Lima; Edwin Tamashiro; Fabrizio R Romano; Marcel M Miyake; Renato Roithmann; Eduardo M Kosugi; Márcio Nakanishi; Marco A Fornazieri; Thiago F P Bezerra; João F Mello; Marcus M Lessa; Richard L Voegels; Otávio B Piltcher; Eulalia Sakano; Fabiana C P Valera Journal: Braz J Otorhinolaryngol Date: 2021-04-03